Probi Mage® to be launched in South Korea with Dongkook Pharmaceutical

Probi has signed a distribution agreement with Dongkook Pharmaceutical Co.,
Ltd., based in Seoul, South Korea for the distribution of Probi´s gut health
product, Probi Mage®. The Product will be launched under Probi’s brand in South
Korea in the second quarter of 2014.

Established in 1968 and listed in KOSDAQ in 1997, Dongkook is the  leading OTC
pharmaceutical company in Korea with own research and production facilities. As
an R&D and technology innovation focused pharmaceutical company, Dongkook
exports their products to more than 50 countries, including 10 countries in the
EU. Dongkook will launch Probi Mage® as a dietary supplement in department
stores and TV/Internet home shopping, one of the largest distribution channels
for dietary supplement products in Korea.

“We are looking forward to launch the Swedish brand Probi Mage® in Korea. Probi
Mage®, based on a high-quality probiotic ingredient with good clinical
documentation, fits well into our dietary supplement range. This is the start of
a long-term relationship with Probi, with the intention to extend the
collaboration in the future.” says Hee Sup Kim, Vice President at Dongkook
Pharmaceutical.

“South Korea is the third largest probiotic supplement market in Asia and we are
looking forward to launching Probi Mage®together with Dongkook Pharmaceutical in
the growing Korean market.” says Peter Nählstedt, CEO of Probi.

The South Korean market for probiotic supplements is estimated to have a value
of USD 54 million, and its annual growth rate over the past five years has been
on avarage 15 percent. The increasing health awareness and disposable income are
positive factors driving the market growth in Korea.

Peter Nählstedt adds “Expansion in the highly populated markets in Asia is a key
component in Probi’s business strategy and the company is looking at extending
its presence further, both in Korea and the rest of the region.”

Probi Mage® is based on Lactobacillus plantarum 299v (DSM 9843), which targets
bloating, gas formation and pain, common symptoms that are sometimes mild or
temporary but often more severe and diagnosed as IBS.

The information is such that Probi AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e
-mail: peter.nahlstedt@probi.se
Niklas Bjärum, VP Marketing & Sales, Probi, tel +46 46 286 89 67 or mobile
+46 705 38 88 64, e-mail: niklas.bjarum@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded biotechnology company that develops
effective and well-documented probiotics. Through its research, Probi has
created a strong product portfolio in the gastrointestinal health and immune
system areas. The products are available to consumers in more than 30 countries
worldwide.  The customers are leading food, health-product and pharmaceutical
companies in the Functional Food and Consumer Healthcare segments. Probi had
sales of MSEK 102 in 2013. The Probi share is listed on NASDAQ OMX Stockholm,
Small-cap. Probi has approximately 4,000 shareholders. Read more on
www.probi.se.

ABOUT DONGKOOK PHARMACEUTICAL CO., LTD.
Read more on http://www.dkpharm.co.kr/eng_index.asp.